rac-Ruxolitinib-d9 (major)
| Product Name | rac-Ruxolitinib-d9 (major) |
|---|---|
| Alternate Names | Ruxolitinib Stable Isotopes, Stable Isotopes of Ruxolitinib |
| CAT No. | CS-T-93835 |
| CAS No. | 941688-05-7 (unlabelled) |
| Category | Stable Isotopes |
| Stock | IN-Stock |
| Mol. Wt. | 315.42 g/mol |
| Mol. For. | C₁₇H₉D₉N₆ |
| Hazardous | This is a Hazardous Compound |
| COA | View Sample COA |
| MSDS | View Sample MSDS |
| Parent API | Ruxolitinib |
| Smileys | N#CCC(N1C=C(C2=C3C=CNC3=NC=N2)C=N1)C4([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C4([2H])[2H] |
| Canonical Smiles | C1CCC(C1)C(CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3 |
| InchIKey | HFNKQEVNSGCOJV-UHFFFAOYSA-N |
| Inchl | InChI=1S/C17H18N6/c18-7-5-15(12-3-1-2-4-12)23-10-13(9-22-23)16-14-6-8-19-17(14)21-11-20-16/h6,8-12,15H,1-5H2,(H,19,20,21) |
| IUPAC | 3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile |
| Controlled | No |
| Shipping | Free for purchase above 1000$ |
| Delivery | In-Stock, products will be dispatched within 24 hours via FedEx for USA, Europe, and other countries. |
| Return | Returns/replacement accepted if you are not satisfied with the quality of the product, (please send us an email with the reason/issues which are facing, within 15 days, after receipt of the product). |
| Ordering | Place your order online or by email sales@clearsynth.com |
Rac-Ruxolitinib-d9 (major) is a deuterated form of the drug Ruxolitinib. It is a selective inhibitor of Janus kinase (JAK) 1 and 2, which are enzymes involved in the signaling pathways of various cytokines and growth factors. Ruxolitinib has been approved by the FDA for the treatment of myelofibrosis and polycythemia vera, both of which are blood disorders. Rac-Ruxolitinib-d9 (major) is a research tool used in the development of new drugs and therapies.
Deuterium is a non-radioactive isotope of hydrogen that has an additional neutron. It is often used in the synthesis of drugs to improve their efficacy and reduce toxicity. Rac-Ruxolitinib-d9 (major) is a deuterated form of Ruxolitinib, which means that the molecule contains nine deuterium atoms. This modification can affect the pharmacokinetics and pharmacodynamics of the drug.
The usage of Rac-Ruxolitinib-d9 (major) is mainly in preclinical studies, where it is used as a reference standard for drug development. It is used to study the metabolic fate and pharmacokinetics of Ruxolitinib in animals and humans. The deuterated form of the drug can help researchers to determine the routes of metabolism, the rate of clearance, and the binding affinity of the drug to its target proteins.
In summary, Rac-Ruxolitinib-d9 (major) is a deuterated form of the drug Ruxolitinib, used as a research tool in preclinical studies. It inhibits JAK 1 and 2 enzymes and is approved for the treatment of blood disorders. Its deuterated form can help in understanding the pharmacokinetics and pharmacodynamics of the drug.
Get an Instant Quote
Related Compounds
rac-Ruxolitinib-d8 | Ruxolitinib D4 | Ruxolitinib D9 |